<DOC>
	<DOC>NCT00420316</DOC>
	<brief_summary>To assess the long-term efficacy and safety of the subjects during the third year after priming with 2 doses of GSK Biologicals' oral live attenuated HRV vaccine (Rotarix) in the primary vaccination study (102247). The Rotarix vaccine was administered in the primary vaccination study. There was no vaccine/intervention in this long-term efficacy study.</brief_summary>
	<brief_title>Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.</brief_title>
	<detailed_description />
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male or female who has completed the second year efficacy followup of the primary vaccination study in Finland. Written informed consent obtained from the parent or guardian of the subject.</criteria>
	<gender>All</gender>
	<minimum_age>32 Months</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Intussusception</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Finland</keyword>
</DOC>